Home / Health / Withdrawal of blood pressure: Irbesartan brings cancer risk

Withdrawal of blood pressure: Irbesartan brings cancer risk



The amounts of a carcinogen revealed in the tests have forced a pharmaceutical company to withdraw irbesartan blood pressure medications, USA Today reported.

According to the report, Prinston Pharmaceuticals found unacceptable levels of nitrosodiethylamine, a probable carcinogen, in the medication, recalling seven batches of tablets of irbesartan HCTZ and one of irbesartan.

The tablets were manufactured in China at Zhejiang Huahai Pharmaceuticals, which has been linked to several withdrawals of blood pressure medications since July, according to USA Today.

All new shipments of medicines from Zhejiang Huahai have been stopped by the Food and Drug Administration, which issued the warning letter. Hetero Labs Limited of India has also been linked to several withdrawals, according to the report.

Here are the tablets at the withdrawal of Prinston Pharmaceuticals, according to USA Today:

  • Irbesartan, 300 mg, 90 units, lot number 331B18009, expires in February 2021.
  • Irbesartan HCTZ, 300 mg / 12.5 mg, account 30, lot number 327A18001, expires in March 2021.
  • Irbesartan HCTZ, 300 mg / 12.5 mg, lot number 327A18002, expires in March 2021.
  • Irbesartan HCTZ, 300 mg / 12.5 mg, count 90, lot number 327B18008, expires in March 2021.
  • Irbesartan HCTZ, 300 mg / 12.5 mg, 90 units, lot number 327B18009, expires in March 2021.
  • Irbesartan HCTZ, 150 mg / 12.5 mg 30 count, lot number 325D18004, expires in March 2021.
  • Irbesartan HCTZ, 150 mg / 12.5 mg, count 90, lot number 325B18004, expires in March 2021.
  • Irbesartan HCTZ, 150 mg / 12.5 mg, count 30, lot number 325D18005 due in March 2021.

Consult your doctor before stopping your medication, as stopping the medication could cause more immediate damage, according to the company.

Check the FDA website for a complete list of recalled drugs or consult your pharmacist.

© 2019 Newsmax. All rights reserved.


Source link